IVERIC bio Inc (ISEE)


Stock Price Forecast

July 11, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading IVERIC bio Inc chart...

About the Company

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases.

Employees

57

CEO

David Guyer

Exchange

NASDAQ

Website

www.ivericbio.com

$210M

Total Revenue

57

Employees

$1B

Market Capitalization

-8.90

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ISEE News

Astellas to Buy Eye-Drug Maker Iveric Bio for $5.9 Billion

10mon ago, source: Hosted on MSN

(Bloomberg) -- Japanese drugmaker Astellas Pharma Inc. agreed to acquire Iveric Bio Inc., a developer of drugs to treat age-related blindness, for about $5.9 billion. The deal, which will be ...

First Republic sinks after JPMorgan takeover, while Norwegian Cruise, Lordstown Motors and SoFi shares are also on the move

10mon ago, source: Hosted on MSN

Shares of Iveric Bio Inc. jumped 14% after Japan’s Astellas Pharma Inc. said it would acquire the biopharmaceutical company for about $5.9 billion, or $40 per share in cash, a nearly 22% premium ...

Versant Venture Capital IV, L.P.'s Net Worth

4d ago, source: Benzinga.com

Who is Versant Venture Capital IV, L.P.? Versant Venture Capital IV, L.P. has an estimated net worth of $7.76 Million. This is based on reported shares across multiple companies, which include ...

EyePoint Pharmaceuticals Announces Appointment of Ramiro Ribeiro, M.D., Ph.D. as Chief Medical Officer

14d ago, source:

Company on-track to report topline data in 2Q 2024 for the Phase 2 PAVIA clinical trial of EYP-1901 in moderately severe-to-severe NPDR –– ...

bluebird bio, Inc. (BLUE)

8d ago, source: Yahoo Finance

SOMERVILLE, Mass., March 11, 2024--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio") today announced it has signed its first Medicaid outcomes-based agreement for LYFGENIA™ (lovotibeglogene ...

Versant Side Fund IV, L.P.'s Net Worth

1mon ago, source: Benzinga.com

Who is Versant Side Fund IV, L.P.? Versant Side Fund IV, L.P. has an estimated net worth of $7.71 Million. This is based on reported shares across multiple companies, which include Oyster Point ...

TRML Tourmaline Bio, Inc.

3d ago, source: Seeking Alpha

Tourmaline Bio, Inc. operates as a clinical biotechnology company that develops medicines for patients with life-altering immune diseases. It develops TOUR006, a human anti-IL-6 monoclonal ...

Gossamer Bio Inc GOSS

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

NUUU Rejuvel Bio-Sciences, Inc.

5d ago, source: Seeking Alpha

Rejuvel Bio-Sciences, Inc., a development stage company, produces, distributes, markets, and sells skin care products worldwide. The company primarily offers skin cream under the Rejuvel brand.

Palisade Bio, Inc.

3y ago, source: CNN

Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post ...

bluebird bio, Inc.

1mon ago, source: CNN

bluebird bio, Inc. is a clinical-stage biotechnology company, which engages in researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...